As of July 8, 2013 - protocols do open and close daily.
Please check with your physician for additional protocols and/or information.
1. E3A06: Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic Smoldering Multiple Myeloma
This research study is being done because there is no current therapy proven to benefit patients with high-risk asymptomatic myeloma, a type of blood cell cancer that has not yet damaged body tissue and organs to the point where symptoms are noticeable. These patients are not treated unless their disease progresses to symptomatic myeloma.
The purpose of this study is to find out what effects (good and bad) the use of the drug lenalidomide has on you and your multiple myeloma, and to compare this with patients that receive no therapy.
2. S1211: A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide with or without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)
One of the standard treatments for your type of cancer is the combination of bortezomib, lenalidomide and dexamethasone (RVD). Elotuzumab is an experimental cancer drug. It is currently being tested in cancer patients. There are laboratory results that suggest that RVD might work better if elotuzumab is added.
For more information on these protocols or any other research, please contact your physician or our clinical research coordinator, Jessica Gerlach, CCRP at 845-333-1133.